Takeya ADACHI, M.D., Ph.D. is a Vice Director of Allergy Center, Keio University Hospital/an Assistant Professor of Department of Dermatology, Keio University School of Medicine/Kyoto Prefectural University of Medicine. He is the president of the NPO United Japanese-researchers Around-the-world (UJA); the vice-president/founder of the NPO Cheiron Initiative; a Japanese Dermatological Association Board Certified Dermatologist; a Japanese Society of Allergology Board Certified Allergologist; a Designated Physician for Rare/Intractable Diseases; and has received a certificate in Health Technology Assessment Expert Program from the University of Tokyo Graduate School of Public Health.After he received M.D. in Keio University School of Medicine, Tokyo, Japan, he majored in medicine to shed light on the novel immunological insights in the context of skin T cell homeostasis and lymphoma (Adachi et al.: Nat. Med. 2015) and received Ph.D. in Keio University Graduate School of Medicine in 2016. His research interests include dermatology, immunology, allergy as well as rare and intractable drug hypersensitivities, and since 2020, he has promoted international collaborative research with the Immunologie, Immunopathologie et Chimie Thérapeutique, CNRS UPR3572, Institut de Biologie Moléculaire et Cellulaire (IBMC), Université de Strasbourg, France, as its former Professeur invité. Upon his experience as a visiting scientist at the secretariat of Human Frontier Science Program (HFSP), a Program Officer in the Japanese governmental R&D funding agency, AMED (Adachi et al.: EJHG 2017, OJRD 2018, Springer-Nature White Paper 2019), and an Interdisciplinary Scientific Committee member of the International Rare Diseases Research Consortium (IRDiRC), he is in charge of the ENGAGE Task Force supported by the Ministry of Health, Labour and Welfare of Japan to implement a national research strategy toward 2030 for allergy/immunology (Adachi et al.: Allergol Int 2020). Currently, he is taking the lead role in developing the Cross-Reality (XR) platform and novel impact analysis (Adachi et al.: Allergy 2022), promoting science without borders to form a society in which people live long, healthy lives, that is.